Reprogramming Cells May Advance Treatment of Blood Disorders
Published on in CHOP News
Skip to content
Published on in CHOP News
August 1, 2013 — First produced only in the past decade, human induced pluripotent stem cells (iPSCs) are capable of developing into many or even all human cell types. In new research, scientists reprogrammed skin cells from patients with rare blood disorders into iPSCs, highlighting the great promise of these cells in advancing understanding of those challenging diseases — and eventually in treating them.
“The technology for generating these cells has been moving very quickly,” said hematologist Mitchell J. Weiss, MD, PhD, corresponding author of two recent studies led by The Children’s Hospital of Philadelphia (CHOP). “These investigations can allow us to better understand at a molecular level how blood cells go wrong in individual patients — and to test and generate innovative treatments for the patients’ diseases.”
Weiss, with Monica Bessler, MD, Philip Mason, PhD, and Deborah L. French, PhD, all of CHOP, led a study on iPSCs and Diamond-Blackfan anemia (DBA) published online June 6 in Blood. Another study by Weiss, French and colleagues in the same journal on April 25 focused on iPSCs in juvenile myelomonocytic leukemia (JMML).
In DBA, a mutation prevents a patient’s bone marrow from producing normal quantities of red blood cells, resulting in severe, sometimes life-threatening anemia. This basic fact makes it difficult for researchers to discern the underlying mechanism of the disease: “It’s very difficult to figure out what’s wrong, because the bone marrow is nearly empty of these cells,” said Bessler, the director of CHOP’s Pediatric and Adult Comprehensive Bone Marrow Failure Center.
The study team removed fibroblasts (skin cells) from DBA patients, and in cell cultures, using proteins called transcription factors, reprogrammed the cells into iPSCs. As those iPSCs were stimulated to form blood tissues, like the patient’s original mutated cells, they were deficient in producing red blood cells.
However, when the researchers corrected the genetic defect that causes DBA, the iPSCs developed into red blood cells in normal quantities. “This showed that in principle, it’s possible to repair a patient’s defective cells,” said Weiss.
Weiss cautioned that this proof-of-principle finding is an early step, with many further studies to be done to verify if this approach will be safe and effective in clinical use.
However, he added, the patient-derived iPSCs are highly useful as a model cell system for investigating blood disorders. For instance, DBA is often puzzling, because two family members may have the same mutation, but only one may be affected by the disease. Because each set of iPSCs is specific to the individual from whom they are derived, researchers can compare the sets to identify molecular differences, such as a modifier gene active in one person but not the other.
Furthermore, the cells offer a renewable, long-lasting model system for testing drug candidates or gene modifications that may offer new treatments, personalized to individual patients.
The second study in Blood provides a concrete example of using iPSCs for drug testing, specifically for the often-aggressive childhood leukemia, juvenile myelomonocytic leukemia (JMML). First the study team generated iPSCs from two children with JMML, and then manipulated the iPSCs in cell cultures to produce myeloid cells that multiplied uncontrollably, much as the original JMML cells do.
They then tested the cells with two drugs, each able to inhibit a separate protein known to be highly active in JMML. One drug, an inhibitor of the MEK kinase, reduced the proliferation of cancerous cells in culture. “This provides a rationale for a potential targeted therapy for this specific subtype of JMML,” said Weiss.
A stem cell core facility at CHOP, directed by study co-author Deborah French under the auspices of the hospital’s Center for Cellular and Molecular Therapeutics, generated the iPSCs lines used in these studies. The facility’s goal is to develop and maintain standardized iPSCs lines specific to a variety of rare inherited diseases — not only DBA and JMML, but also dyskeratosis congenita, congenital dyserythropoietic anemia, thrombocytopenia absent radii (TAR), Glanzmann’s thrombasthenia and Hermansky-Pudlak syndrome.
A longer-term goal, added Weiss, is for the iPSC lines to provide the raw materials for eventual cell therapies that could be applied to specific genetic disorders. “The more we learn about the molecular details of how these diseases develop, the closer we get to designing precisely targeted tools to benefit patients.”
The National Institutes of Health (grants HL101606, DK090969) supported both studies. Also supporting the Diamond Blackfan anemia study were the U.S. Department of Defense (grant BM090168), and NIH grants CA106995, CA105312, RR024134, and TR000003. Other funders of the JMML study were NIH grants HL099656 and CA082103, the Cookies for Kids’ Cancer Foundation, the Leukemia and Lymphoma Society and the Frank A. Campini Foundation. Weiss’s research on stem cells is also supported by the Jane Fishman Grinberg Endowed Chair and Bessler receives support from the Buck Family Endowed Chair in Hematology.
“Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients,” Blood, published online June 6, 2013.
“Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia,” Blood, published online April 25, 2013.
John Ascenzi, Children's Hospital of Philadelphia, 267-426-6055, firstname.lastname@example.org